1. Home
  2. PRLD vs LITM Comparison

PRLD vs LITM Comparison

Compare PRLD & LITM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • LITM
  • Stock Information
  • Founded
  • PRLD 2016
  • LITM 2018
  • Country
  • PRLD United States
  • LITM Canada
  • Employees
  • PRLD N/A
  • LITM N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • LITM Other Metals and Minerals
  • Sector
  • PRLD Health Care
  • LITM Basic Materials
  • Exchange
  • PRLD Nasdaq
  • LITM Nasdaq
  • Market Cap
  • PRLD 73.7M
  • LITM 64.8M
  • IPO Year
  • PRLD 2020
  • LITM 2021
  • Fundamental
  • Price
  • PRLD $1.05
  • LITM $0.89
  • Analyst Decision
  • PRLD Strong Buy
  • LITM
  • Analyst Count
  • PRLD 2
  • LITM 0
  • Target Price
  • PRLD $4.50
  • LITM N/A
  • AVG Volume (30 Days)
  • PRLD 611.2K
  • LITM 106.9M
  • Earning Date
  • PRLD 02-13-2025
  • LITM 10-30-2024
  • Dividend Yield
  • PRLD N/A
  • LITM N/A
  • EPS Growth
  • PRLD N/A
  • LITM N/A
  • EPS
  • PRLD N/A
  • LITM N/A
  • Revenue
  • PRLD $3,000,000.00
  • LITM N/A
  • Revenue This Year
  • PRLD N/A
  • LITM N/A
  • Revenue Next Year
  • PRLD N/A
  • LITM N/A
  • P/E Ratio
  • PRLD N/A
  • LITM N/A
  • Revenue Growth
  • PRLD N/A
  • LITM N/A
  • 52 Week Low
  • PRLD $0.80
  • LITM $0.15
  • 52 Week High
  • PRLD $6.80
  • LITM $1.88
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 45.27
  • LITM 56.94
  • Support Level
  • PRLD $0.98
  • LITM $0.75
  • Resistance Level
  • PRLD $1.43
  • LITM $0.96
  • Average True Range (ATR)
  • PRLD 0.12
  • LITM 0.26
  • MACD
  • PRLD -0.02
  • LITM -0.02
  • Stochastic Oscillator
  • PRLD 14.14
  • LITM 21.42

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About LITM Snow Lake Resources Ltd.

Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.

Share on Social Networks: